<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="53602">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01848431</url>
  </required_header>
  <id_info>
    <org_study_id>FF-HTC Verson 1-3</org_study_id>
    <nct_id>NCT01848431</nct_id>
  </id_info>
  <brief_title>Randomized Study on the Effects of Moderate Anaemia in Free Microvascular Tissue Transfer</brief_title>
  <official_title>Randomized Study on the Effects of Moderate Anaemia in Free Microvascular Tissue Transfer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <authority>Switzerland: Swissmedic</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The evaluation of Perfusion of free flaps in patients with moderate anaemia and possible
      reduction of the transfusion threshold.

        -  Trial with surgical intervention
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In study group 1 patients will be kept at a hematocrit level below 28% and only receive
      transfusions if symptomatic or the fall below 25%. Patients in group 2 will receive
      transfusions to reach a hematocrit always above 30%.

      Tissue perfusion in free flaps will be measured with indocyanine green fluorescence
      angiography, confocal microscopy and oxygen partial pressure measurement probes.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">October 2015</completion_date>
  <primary_completion_date type="Anticipated">October 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Number of Blood transfusions peri- and postoperative</measure>
    <time_frame>10 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Open Fracture of Foot</condition>
  <condition>Tumor</condition>
  <arm_group>
    <arm_group_label>anaemia group</arm_group_label>
    <description>no blood transfusions will be given until hct falls under 25%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>normal hct group</arm_group_label>
    <description>patients in group 2 will receive transfusions as is currently standard protocol outside the study</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood analysis
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        patients scheduled for defect reconstruction with free flaps and a preoperative hematocrit
        of 28 % or below
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  planned defect reconstruction with free flap and preoperative hematocrit of 28% or
             below

        Exclusion criteria:

          -  coagulation disorder

          -  Jehovah's witness

          -  iodine allergy

          -  renal or hepatic insufficiency
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maurizio Calcagni, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Zurich, Clinic of Reconstructive Surgery</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maurizio Calcagni, MD</last_name>
    <email>maurizio.calcagni@usz.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Zurich, Center for Reconstructive Surgery</name>
      <address>
        <city>Zurich</city>
        <state>ZH</state>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>May 13, 2013</lastchanged_date>
  <firstreceived_date>April 22, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fractures, Open</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
